A clinical trial of Johnson & Johnson’s radiopharmaceutical drug JNJ-6420 for prostate cancer showed promising results with 18% of patients having a complete or partial response. However, four participants in the trial died. The drug is designed to target cancer cells with radioactive isotopes and is being developed for metastatic castration-resistant prostate cancer. This comes in the wake of the approval of Pluvicto, another drug for prostate cancer treatment. Interest in radiopharmaceuticals has grown, with this new data set to be presented at the American Society of Clinical Oncology meeting.
Source link
J&J reports mixed data on next-generation radiopharmaceutical
